Key result
Patients with acute non-cardioembolic ischemic stroke or TIA had higher average baseline platelet p-selectin expression compared to healthy volunteers.
Why the study?
Does antiplatelet therapy suppress baseline platelet p-selectin expression in patients with acute ischemic stroke?
Observational (n=105)
No
Does antiplatelet therapy suppress baseline platelet p-selectin expression in patients with acute ischemic stroke?
Platelet p-selectin expression is significantly elevated in the acute phase of ischemic stroke, but baseline expression is not significantly suppressed by prior antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
Elevated platelet p-selectin in acute non-cardioembolic stroke/TIA was not suppressed by prior antiplatelet therapy; leaves open its role as a therapeutic target.
Aims: The aim of this study was to asses the platelet activation in the acute phase of ischemic stroke and transient ischemic attack (TIA) by defining p-selectin (CD62) expression by flow cytometry in vivo – without stimulation with agonists. We also studied whether antiplatelet therapy supresses the levels of baseline p-selectin expression and verified if there is a correlation between platelet CD62 expression and the type of ischemic stroke. Methods: We determined the expression of platelet surface p-selectin using whole-blood flow cytometry within the first 48-hours after onset of cerebral symptoms in patients with atherothrombotic and lacunar ischemic stroke and in healthy volunteers. We studied the realationship between antiplatelet medication and the type of ischemic stroke to baseline p-selectin expression. Results: Patients with acute cerebral ischemia have an excess of circulating platelets that express p-selectin, compared to healthy volunteers. The difference between average p-selectin expression in the group of healthy volunteers and the group of patients with stroke was statistically significant (p-value < 0,000001). Patients with stroke without antiplatelet medication showed a higher p-selectin expression than patients with antiplatelet medication (ASA, CLP, or ASA and CLP), hovewer, the difference was not statistically significant. There is no relationship between CD62 expression and the type of stroke. Conclusions: We can conclude that p-selectin is a highly sensitive blood biomarker of increased platelet activation. Antiplatelet therapy suppresses baseline p-selectin expression only minimally, insignificantly according to our results.
No takes yet. Share an insight, caveat, or question.
Kalmarova et al. (2018) conducted an observational in Acute ischemic stroke and Transient Ischemic Attack (TIA) (n=105). Acute ischemic stroke or TIA vs. Healthy volunteers was evaluated on Average platelet p-selectin expression (%) (p=<0.000001). Patients with acute non-cardioembolic ischemic stroke or TIA had higher average baseline platelet p-selectin expression compared to healthy volunteers.
Synapse has enriched 10 related papers. Consider them for comparative context: